slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 225,751-225,780
Pages 10,126
Rows per page 30
Component
225,751-225,780 of 303,780
36
The diagram shows the EGFR signaling pathway and the inhibitory effect of ERAS-801.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
37
The slide uses a stacked bar chart to show mutation incidence and a comparison table to contrast clinical outcomes across different indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
39
The chart is a Kaplan-Meier survival plot. The comparison shows ERAS-801 (blue line) outperforming standard EGFR inhibitors (Erlotinib, Lapatinib, Osimertinib) and vehicle control.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
40
The slide displays four distinct survival plots (HK301, GS025, HK336, GS187) showing statistically significant survival improvements (***) with ERAS-801 treatment.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
41
The slide uses a waterfall plot to show individual model responses and pie charts to summarize efficacy across the total cohort vs. the specific EGFR-mutant/amplified subset.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
42
The slide uses a table format to communicate a product roadmap for clinical development.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
43
Erasca | Investor Presentation Deck | 56 slidesErasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Potential impact and investment thesis1 hit
44
Features the Erasca logo and a Lorenz attractor-style graphic.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Potential impact and investment thesis1 hit
45
The slide uses a matrix-like layout to compare drug candidates by development stage and company, with a callout box for competitive advantages.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
46
The slide uses a bullseye/concentric circle framework to communicate strategic prioritization of clinical trials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
47
The slide uses a contrast-based layout to frame the subject as a winner in a difficult therapeutic space.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
48
The slide uses western blot data to demonstrate the superiority of ERAS-007 in a specific biological pathway context.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
49
Includes RECIST 1.1 criteria reference and patient progression note.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
50
The chart displays individual patient responses to treatment, with bars colored by dosage level.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
51
The chart displays individual patient treatment timelines, with markers for partial response, stable disease, and progressive disease.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
52
Data from HERKULES-1 study, cutoff 23 May 2022.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
53
The slide uses a line chart to show concentration over time and a table to summarize key PK metrics (Cmax, Cmin, T>IC90, T<IC50) for five different dosing regimens.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
54
The slide uses a comparative layout contrasting a list of competitor assets with the specific benefits of the company's own asset (ERAS-601).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
55
The slide uses a biological pathway diagram to illustrate the mechanism of action.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
56
The slide contrasts intermittent high-coverage dosing (ERAS-007) with sustained steady-state coverage (ERAS-601) to manage efficacy vs. toxicity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
01
Essity | Investor Presentation Deck | 13 slidesEssity | Investor Presentation Deck | 13 slides · Essity
Conference presentation Investor relations Beat · Attention1 hit
04
The slide highlights the scale of the company (billion people, 150 countries) and displays a portfolio of brand logos.Essity | Investor Presentation Deck | 13 slides · Essity
Conference presentation Investor relations 1 hit
05
Essity | Investor Presentation Deck | 13 slidesEssity | Investor Presentation Deck | 13 slides · Essity
Conference presentation Investor relations Beat · Key Messages1 hit
06
The slide uses a combination of bar charts for absolute values and overlaid circles/labels for percentages.Essity | Investor Presentation Deck | 13 slides · Essity
Conference presentation Investor relations Beat · DesireLoop · Cost Of Inaction1 hit
07
The slide uses a timeline-style visual to represent distinct strategic pillars.Essity | Investor Presentation Deck | 13 slides · Essity
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
08
Essity | Investor Presentation Deck | 13 slidesEssity | Investor Presentation Deck | 13 slides · Essity
Conference presentation Investor relations Beat · InterestLoop · Cost Of Inaction1 hit
09
The charts show annual data from 2014-2022 and a year-to-date 9M 2023 figure. The 9M 2023 bars are segmented by quarter.Essity | Investor Presentation Deck | 13 slides · Essity
Conference presentation Investor relations Beat · Solution Provide ReliefLoop · Cost Of Inaction1 hit
10
The chart combines historical bar data with a waterfall bridge to illustrate future growth drivers.Essity | Investor Presentation Deck | 13 slides · Essity
Conference presentation Investor relations Beat · ClimaxLoop · Why Now1 hit
11
Includes company logo and a brand portfolio bar at the bottom.Essity | Investor Presentation Deck | 13 slides · Essity
Conference presentation Investor relations 1 hit